Skip to content

Marketing and Use of QuantiFERON-TB Gold

14 May 2013 Peer M. Schatz Chief Executive Officer and Managing Director QIAGEN Benelux B.V. Spoorstraat 50 5911 KJ Venlo The Netherlands Email: RE: Marketing and Use of QuantiFERON-TB Gold for active TB in India and high TB burden…

Read more

TAG and the TB CAB Send Open Letter to Otsuka

TAG and the TB CAB send open letter to Otsuka to expedite plans to develop a pre-approval access program for delamanid for patients in urgent need, determine if delamanid is safe to use with bedaquiline, and develop the drug for pediatric use as rapidly and safely as possible.
Read more

TAG and TB CAB Issue Open Letter to Janssen

TAG and TB CAB issue an open letter to Janssen, bedaquiline’s sponsor, about the need to accelerate pediatric research, to determine the safety of using bedaquiline and delamanid together, and to support Janssen’s compassionate use program to provide access to bedaquiline for people in urgent need in places where the drug has not yet been approved.
Read more

Letter to NIAID Director Anthony Fauci Opposing the HVTN 505 Vaccine Trial

TAG has previously expressed opposition to the PAVE100A vaccine trial involving the Vaccine Research Center’s DNA and Ad5 candidate(i). With the recent presentation by Dan Barouch of new macaque challenge data involving a DNA/adenovirus prime-boost regimen at the 2009 Keystone meeting(ii), we now must vociferously oppose the proposed descendant of PAVE100A, the HVTN 505 trial.
Read more
Back To Top